Q1 2022 EPS Estimates for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Reduced by Jefferies Financial Group

Vanda Pharmaceuticals Inc. (NASDAQ:VNDAGet Rating) – Analysts at Jefferies Financial Group cut their Q1 2022 EPS estimates for Vanda Pharmaceuticals in a note issued to investors on Sunday, April 24th. Jefferies Financial Group analyst C. Howerton now anticipates that the biopharmaceutical company will post earnings per share of ($0.01) for the quarter, down from their previous forecast of $0.02. Jefferies Financial Group currently has a “Hold” rating and a $12.00 target price on the stock. Jefferies Financial Group also issued estimates for Vanda Pharmaceuticals’ FY2022 earnings at $0.39 EPS and FY2026 earnings at $0.96 EPS.

Vanda Pharmaceuticals (NASDAQ:VNDAGet Rating) last announced its quarterly earnings results on Wednesday, February 23rd. The biopharmaceutical company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.03. The company had revenue of $68.02 million during the quarter, compared to analyst estimates of $65.90 million. Vanda Pharmaceuticals had a return on equity of 6.81% and a net margin of 12.34%. During the same period in the prior year, the company earned $0.15 earnings per share.

VNDA has been the subject of a number of other research reports. Zacks Investment Research upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, March 8th. TheStreet lowered shares of Vanda Pharmaceuticals from a “b-” rating to a “c” rating in a research note on Wednesday, February 9th. Finally, StockNews.com upgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 26th. Two research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Vanda Pharmaceuticals has a consensus rating of “Buy” and an average price target of $18.00.

NASDAQ VNDA opened at $10.79 on Tuesday. Vanda Pharmaceuticals has a fifty-two week low of $10.60 and a fifty-two week high of $21.86. The stock has a 50-day simple moving average of $11.68 and a two-hundred day simple moving average of $14.74. The firm has a market capitalization of $603.24 million, a P/E ratio of 18.60 and a beta of 0.54.

In related news, CFO Kevin Patrick Moran sold 3,473 shares of Vanda Pharmaceuticals stock in a transaction that occurred on Tuesday, March 1st. The shares were sold at an average price of $11.19, for a total value of $38,862.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CMO Joakim Wijkstrom sold 6,974 shares of the business’s stock in a transaction on Wednesday, March 2nd. The shares were sold at an average price of $11.19, for a total transaction of $78,039.06. The disclosure for this sale can be found here. Insiders sold 30,015 shares of company stock valued at $334,662 in the last quarter. Corporate insiders own 6.10% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. lifted its holdings in shares of Vanda Pharmaceuticals by 1.3% during the 4th quarter. BlackRock Inc. now owns 9,825,375 shares of the biopharmaceutical company’s stock valued at $154,158,000 after buying an additional 123,253 shares during the last quarter. Macquarie Group Ltd. raised its holdings in shares of Vanda Pharmaceuticals by 1.0% during the 3rd quarter. Macquarie Group Ltd. now owns 3,236,524 shares of the biopharmaceutical company’s stock worth $55,474,000 after buying an additional 31,688 shares in the last quarter. LSV Asset Management grew its position in shares of Vanda Pharmaceuticals by 6.2% in the 4th quarter. LSV Asset Management now owns 2,260,482 shares of the biopharmaceutical company’s stock valued at $35,467,000 after buying an additional 131,385 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Vanda Pharmaceuticals by 5.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,033,578 shares of the biopharmaceutical company’s stock worth $31,909,000 after acquiring an additional 103,696 shares in the last quarter. Finally, Epoch Investment Partners Inc. increased its position in shares of Vanda Pharmaceuticals by 7.4% during the third quarter. Epoch Investment Partners Inc. now owns 1,980,897 shares of the biopharmaceutical company’s stock valued at $33,953,000 after acquiring an additional 136,207 shares during the last quarter. Institutional investors and hedge funds own 99.12% of the company’s stock.

Vanda Pharmaceuticals Company Profile (Get Rating)

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

Featured Articles

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.